BioMarin Pharmaceutical Securities Litigation

This official website is maintained by the Notice Administrator supervised by Lead Counsel in the action entitled In re BioMarin Pharmaceutical Inc. Securities Litigation, Case 3:20-cv-06719-WHO (N.D. Cal.) (the “Action”) pending in the United States District Court for the Northern District of California.

The information contained on this web page is only a summary of information presented in more detail in the Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys’ Fees and Litigation Expenses (“Notice”), which you can access by clicking here. Since this website is just a summary, you should review the Notice for additional details.

The Court-appointed Lead Plaintiff Arbejdsmarkedets Tillægspension (“Lead Plaintiff”), on behalf of itself and the Settlement Class, has settled the Action for $39,000,000 in cash (“Settlement”).

On November 8, 2023, the Court held a hearing to consider final approval of the Settlement and other matters. On November 14, 2023, the Court entered a final order approving the Settlement and Plan of Allocation and Lead Counsel’s motion for attorney's fees and litigation expenses, and a final Judgment.

The claims administration concluded in April 2024. On April 15, 2024, Lead Counsel filed a Motion for Approval of Distribution Plan seeking the Court’s permission to distribute the net settlement fund to Court-approved eligible claimants. On May 3, 2024, the Court granted permission for the net settlement fund to be distributed, the distribution of funds will occur thereafter within 4 – 6 weeks.

If you have questions, you may call the BioMarin Pharmaceutical Securities Settlement Helpline at (877) 390-3369 or email